Forest Builds On Saunders’ Strategy With $2.9B Aptalis Buy
This article was originally published in The Pink Sheet Daily
Executive Summary
The specialty pharma makes its first acquisition of the New Year, tucking in gastrointestinal and cystic fibrosis franchises, which bolster its current therapeutic area offerings.
You may also be interested in...
With Ikaria and Aptalis, Private Equity Investors Get Creative To Cash Out
Ikaria shareholders sold the commercial side of that critical care business, but retained a stake in the off-loaded assets. While gastrointestinal and cystic fibrosis company Aptalis turns to an IPO instead of an acquisition.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.